Prosecution Insights
Prosecution Insights
10 pending office actions • 10 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 9 (90%) |
| §112 only | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAJILIG, CHRISTINE T | 1 | 70.7% | +14.8% |
| PROSSER, ALISSA J | 1 | 15.9% | +12.1% |
| ROTONDI, CONNOR JON | 1 | — | — |
| KIM, BRYAN | 1 | 28.7% | +36.7% |
| SCHACHERMEYER, SAMANTHA LYNN | 1 | 36.7% | +65.0% |
| DAVIS, SHARON M | 1 | 68.0% | +27.4% |
| PRONZATI, GINA | 1 | 66.7% | +41.7% |
| DORNA, CARRIE R | 1 | 72.2% | +28.3% |
| DONOHUE, SEAN R | 1 | 41.5% | +21.7% |
| HUDSON, AMY ROSE | 1 | 75.1% | +11.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546637 | PULSE PROTEIN GELATION | KIM, BRYAN | 8d |
| 18691738 | SYNERGISTIC NANOMEDICINE DELIVERING TOPOISOMERASE I TOXIN (SN-38) AND INHIBITORS OF POLYNUCLEOTIDE KINASE 3'-PHOSPHATASE (PNKP) FOR ENHANCED TREATMENT OF COLORECTAL CANCER | PROSSER, ALISSA J | 53d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625545 | EXONS 45-55 SKIPPING USING MUTATION-TAILORED COCKTAILS OF ANTISENSE MORPHOLINOS IN THE DMD GENE | HUDSON, AMY ROSE | 71d overdue |
| 18719483 | SMART FRICTION PENDULUM SYSTEM | CAJILIG, CHRISTINE T | 66d overdue |
| 18279517 | THE USE OF EMPAGLIFLOZIN FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE | SCHACHERMEYER, SAMANTHA LYNN | 46d overdue |
| 17886881 | THREE-DIMENSIONAL (3D) HERNIA PLUG DEVICE AND A METHOD OF MANUFACTURING THEREOF | DORNA, CARRIE R | 43d overdue |
| 18037196 | CYCLOTRON TARGET AND LANTHANUM THERANOSTIC PAIR FOR NUCLEAR MEDICINE | DAVIS, SHARON M | 35d overdue |
| 18163816 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | PRONZATI, GINA | 32d overdue |
| 18546637 | PULSE PROTEIN GELATION | KIM, BRYAN | 8d |
| 17725271 | BIOREDUCTIVELY-ACTIVATED COMPOUNDS, THEIR PRODRUGS, RADIOPHARMACEUTICALS, THE COMPOSITIONS, AND THEIR APPLICATIONS IN MULTIMODAL THERANOSTIC MANAGEMENT OF HYPOXIA DISEASES INCLUDING CANCER | DONOHUE, SEAN R | 29d |
| Art Unit | Apps |
|---|---|
| 3633 | 1 |
| 1619 | 1 |
| 1779 | 1 |
| 1792 | 1 |
| 1693 | 1 |
| 3646 | 1 |
| 1633 | 1 |
| 3791 | 1 |
| 1618 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719483 | SMART FRICTION PENDULUM SYSTEM | CAJILIG, CHRISTINE T | 3633 | §103 | Non-Final OA | 66d overdue | Pending | Jun 13, 2024 |
| 18691738 | SYNERGISTIC NANOMEDICINE DELIVERING TOPOISOMERASE I TOXIN (SN-38) AND INHIBITORS OF POLYNUCLEOTIDE KINASE 3'-PHOSPHATASE (PNKP) FOR ENHANCED TREATMENT OF COLORECTAL CANCER | PROSSER, ALISSA J | 1619 | §103 | Non-Final OA | 53d | Pending | Mar 13, 2024 |
| 18290853 | METHOD OF SLUDGE PRETREATMENT FOR IMPROVED DIGESTIBILITY AND REDUCED SCALING | ROTONDI, CONNOR JON | 1779 | §103 | Non-Final OA | 15d | Pending | Jan 22, 2024 |
| 18546637 | PULSE PROTEIN GELATION | KIM, BRYAN | 1792 | §112 | Non-Final OA | 8d | Pending | Aug 30, 2023 |
| 18279517 | THE USE OF EMPAGLIFLOZIN FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Non-Final OA | 46d overdue | Pending | Aug 30, 2023 |
| 18037196 | CYCLOTRON TARGET AND LANTHANUM THERANOSTIC PAIR FOR NUCLEAR MEDICINE | DAVIS, SHARON M | 3646 | §103 | Non-Final OA | 35d overdue | Pending | May 16, 2023 |
| 18163816 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | PRONZATI, GINA | 1633 | §103 | Non-Final OA | 32d overdue | Pending | Feb 02, 2023 |
| 17886881 | THREE-DIMENSIONAL (3D) HERNIA PLUG DEVICE AND A METHOD OF MANUFACTURING THEREOF | DORNA, CARRIE R | 3791 | §103 | Non-Final OA | 43d overdue | Pending | Aug 12, 2022 |
| 17725271 | BIOREDUCTIVELY-ACTIVATED COMPOUNDS, THEIR PRODRUGS, RADIOPHARMACEUTICALS, THE COMPOSITIONS, AND THEIR APPLICATIONS IN MULTIMODAL THERANOSTIC MANAGEMENT OF HYPOXIA DISEASES INCLUDING CANCER | DONOHUE, SEAN R | 1618 | §103 | Final Rejection | 29d | Pending | Apr 20, 2022 |
| 17625545 | EXONS 45-55 SKIPPING USING MUTATION-TAILORED COCKTAILS OF ANTISENSE MORPHOLINOS IN THE DMD GENE | HUDSON, AMY ROSE | 1636 | §103 | Non-Final OA | 71d overdue | Pending | Jan 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial